The Efficacy and Safety of Bevacizumab Plus Anti-PD-1/PD-L1 Inhibitors in Combination with Hepatic Arterial Infusion Chemotherapy for Initially Unresectable Hepatocellular Carcinoma

Xiang Tang,1,2,* Jinbin Chen,1,2,* Wei Peng,1,2,* Zhoutian Yang,1,2 Li Hu,1,2 Zhiwei Ye,1,2 Yizhen Fu,1,2 Dandan Hu,1,2 Zhongguo Zhou,1,2 Minshan Chen,1,2 Yaojun Zhang,1,2 Jun-Cheng Wang1,2 1State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Resear...

Full description

Bibliographic Details

Published in:	ImmunoTargets and Therapy
Main Authors:	Tang X, Chen J, Peng W, Yang Z, Hu L, Ye Z, Fu Y, Hu D, Zhou Z, Chen M, Zhang Y, Wang JC
Format:	Article
Language:	English
Published:	Dove Medical Press 2024-10-01
Subjects:	hepatocellular carcinoma immune checkpoint inhibitor bevacizumab hepatic arterial infusion chemotherapy adverse event
Online Access:	https://www.dovepress.com/the-efficacy-and-safety-of-bevacizumab-plus-anti-pd-1pd-l1-inhibitors--peer-reviewed-fulltext-article-ITT